Sign inJoin waitlistJoin the waitlist

Vaibhav Sahai

Lindsay Olson Pancreatic Cancer Research Professor · University of Michigan

Credentials: · · · · · ·

History

University of Michigan
Present
University of Michigan
Present

Medical Oncology
2007–2009
Internal Medicine
UPMC Medical Education
2004–2007
Bachelor of Medicine, Bachelor of Surgery
2000–2004

Research

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology · 2020 · 1,293 citations
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 829 citations
Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer
Nature Cancer · 2020 · 464 citations

MZ
Mark Zalupski
18 papers
Timothy Frankel
15 papers
Jiaqi Shi
14 papers
Filip Bednar
13 papers
EC
Eileen Carpenter
12 papers · 3 as a fellow
Al Benson
10 papers
Diane Simeone
8 papers
Allison Schulman
6 papers
Davendra Sohal
6 papers
EW
Erik Wamsteker
6 papers
Hidayatullah Munshi
6 papers
Kyle Cuneo
6 papers

Grants

Targeting the RNA Exosome for Cancer Therapeutics
National Cancer Institute · R01
PI · $2.4M · University of Michigan at Ann Arbor
2019–2024

Clinical trials

Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Principal investigator · Not yet recruiting · Phase 2
Midhun Malla
2026–2030
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Principal investigator · Active not recruiting · Phase 2
University of Michigan Rogel Cancer Center
2024–2027
Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas
Principal investigator · Withdrawn · Phase 1, Phase 2
University of Michigan Rogel Cancer Center
2023–2027
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2023–2028